Cohance Lifesciences Q2 Results 2025 Highlights: Net Profit Falls by 46.50% & Revenue Down 7.98% YoY

Click and Sign Up to Get Live Updates on Q2 Results 

Cohance Lifesciences Q2 Results FY26: During Q2 FY26, Cohance Lifesciences’ profit decreased 46.50% YoY, while revenue decreased by 7.98% YoY. The company posted robust numbers, with Q2 PAT at ₹74.08 crores and revenue at ₹555.57 crores. Cohance Lifesciences announced its Q2 results on 12th November 2025.  

Cohance Lifesciences Q2 Results FY26: Extracts of FY25 & FY26

Cohance Lifesciences Q2 Results FY26 Highlights (Q2 FY26 vs FY25)

• Cohance Lifesciences clocked Q2 FY26 consolidated revenue of ₹555.57 crores vs ₹603.77 crores. 
• On the profit front, Cohance Lifesciences earned a consolidated PAT of ₹136.55 crore in Q2 FY26. During FY25, the company’s PAT stood at ₹221.56 crore.
• According to the consolidated figures, Cohance Lifesciences’ quarterly PAT decreased by 46.50% YoY, while revenue increased by 7.98%.
• Cohance Lifesciences clocked Q2 FY26 standalone revenue of ₹497.79 crores vs ₹594.43 crores. 
• On the profit front, Cohance Lifesciences earned a standalone PAT of ₹94.29 crore in Q2 FY26. During FY25, the company’s PAT stood at ₹139.1 crore.
• According to the standalone figures, Cohance Lifesciences’ quarterly PAT decreased by 32.21% YoY, while revenue decreased by 16.26%.

Download the Univest iOS App or Univest Android App to get daily stock recommendations and insightful research pieces!

Cohance Lifesciences Share Price Performance

On the opening bell on 18th November 2025, Cohance Lifesciences shares opened at ₹616.00 per share. However, the initial gains have since eroded, and Cohance Lifesciences shares are currently trading at ₹594.20 per share, which is higher than the opening price.    

Considering the long-term achievements, Cohance Lifesciences shares have yielded returns of approximately -44.39% over the past years, and 5-year returns stand at -45.42%. Over the maximum timeframe, Cohance Lifesciences shares delivered a 45.42% return to investors. 

What Analysts Expect Post Q2 Results?

Following Cohance Lifesciences’ robust Q2 results, analysts expect its share price to rise. According to analysts, Cohance Lifesciences’ share price is expected to reach ₹599.00 per share in the coming year; however, in a downturn, it could fall to ₹590.30 per share. However, one must ignore stock market volatility and invest in Cohance Lifesciences shares after thorough research. 

Disclaimer: Investment in the share market is subject to risk. This news article is for informational purposes only. Conduct your own research before investing in shares and other securities.

Recent Articles

Nestle Q2 Results FY26: Q2 PAT Falls 17.38% to ₹743.17 Crore; Revenue Up 10.57% YoY

Inspira Enterprise India IPO Details: Everything You Should Know about 

Swaraj Engines Q2 Results FY26: Q2 PAT Rises 8.88% to ₹49 Crore; Revenue Up 8.62% YoY

HDB Financial Q2 Results FY26: Q2 PAT Falls 1.5% to ₹581 Crore; Revenue Up 13.42% YoY

BEL Gears Up for Q2 Reveal on 4th November; Check Key Expectations Here

Paytm Gears Up for Q2 Reveal on 4th November; Check Key Expectations Here

Blue Dart Gears Up for Q2 Reveal on 28th October; Check Key Expectations Here